FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

6 Observations in Hetero Labs 483

[ Price : $8.95]

FDA releases the 12-page form FDA-483 with six observations from an inspection at Indias Hetero Labs Unit 9 API manufacturing faci...

Akamis Bio Gets Fast Track for Rectal Cancer Drug

[ Price : $8.95]

FDA grants Akamis Bio a fast-track designation to NG-350A for treating mismatch repair-proficient locally advanced rectal cancer.

Pluses, Minuses to FDA Oncology Trial Guidance

[ Price : $8.95]

Oncologist John Burke analyzes the positive and potentially negative impacts of FDAs new guidance on overall survival as an endpoi...

FDA Clears First 1-Minute HIV Self Test

[ Price : $8.95]

FDA approves a bioLytical Laboratories PMA for the INSTI HIV Self Test, an at-home HIV test that delivers results in 60 seconds or...

Allovate Illegally Marketing Allerdent, FDA Says

[ Price : $8.95]

FDA warns New York, NY-based Allovate Therapeutics that it is illegally marketing its Allerdent toothpaste that is an unapproved n...

LifeVac Marketing Illegal Airway Device: FDA

[ Price : $8.95]

FDA warns Nesconset, NY-based LifeVac that it is illegally marketing and distributing an airway clearance device.

FDA Accepts NDA for Once-Daily ADHD Drug

[ Price : $8.95]

FDA accepts for review a Cingulate NDA for CTx-1301 (dexmethylphenidate), a once-daily stimulant designed to treat attention-defic...

Astellas Pancreatic Cancer Study Misses Endpoint

[ Price : $8.95]

An Astellas Phase 2 study evaluating zolbetuximab in combination with standard chemotherapy for metastatic pancreatic cancer fails...

Leukemia Treatment Data Sets Guidance

[ Price : $8.95]

FDA publishes a guidance with recommendations for submitting clinical trial data sets for response assessments for treatments of a...

Pfizers Tukysa Meets Trial Endpoint

[ Price : $8.95]

Pfizer says its Tukysa met the progression-free survival endpoint in the HER2CLIMB-05 breast cancer trial combining Tukysa with st...